Advertisement
UK markets closed
  • FTSE 100

    8,023.87
    +128.02 (+1.62%)
     
  • FTSE 250

    19,599.39
    +208.09 (+1.07%)
     
  • AIM

    749.18
    +3.51 (+0.47%)
     
  • GBP/EUR

    1.1592
    -0.0015 (-0.13%)
     
  • GBP/USD

    1.2343
    -0.0028 (-0.22%)
     
  • Bitcoin GBP

    53,646.85
    +1,321.66 (+2.53%)
     
  • CMC Crypto 200

    1,393.38
    -12.61 (-0.90%)
     
  • S&P 500

    4,991.14
    +23.91 (+0.48%)
     
  • DOW

    38,126.91
    +140.51 (+0.37%)
     
  • CRUDE OIL

    83.35
    +0.21 (+0.25%)
     
  • GOLD FUTURES

    2,349.90
    -63.90 (-2.65%)
     
  • NIKKEI 225

    37,438.61
    +370.26 (+1.00%)
     
  • HANG SENG

    16,511.69
    +287.55 (+1.77%)
     
  • DAX

    17,860.80
    +123.44 (+0.70%)
     
  • CAC 40

    8,040.36
    +17.95 (+0.22%)
     

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference

Immunocore Holdings Limited
Immunocore Holdings Limited

Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that management will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference.

The presentation is scheduled for Wednesday, January 11, 2023, at 9:00 a.m. Pacific Standard Time (PST).

ADVERTISEMENT

The presentation will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT:

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com